As you probably know Amylin is on sale therefore PR campaign is running:
From here:
Amylin Pharmaceuticals, Inc. (AMLN) and Alkermes plc (ALKS) today announced clinical study results which showed that a significantly greater proportion of patients treated with BYDUREON™ (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, achieved target glucose levels and weight loss compared to those treated with Levemir® (insulin detemir). The study is being presented at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia.
I expect that even more positive results will be disclosed until Amylin is successfully sold.
No comments:
Post a Comment